The usage of anti–PD-1 and anti–PD-L1 antibodies has been remarkably successful, both in terms of response rates (30%–45%) and durability (2–3 years) in melanoma [2, 17–24], even after discontinuation of the treatments [2, 25]. The gene discussed is CD274; the disease is melanoma.